Burning feet, electric shocks, stabbing sensations and pain from ordinary touch can make neuropathy difficult to live with. When gabapentin provides incomplete relief or causes unwanted sleepiness, cannabis may seem like an appealing alternative. Both can influence pain processing, but their evidence, consistency and risks differ substantially. Comparing them requires more than asking which one feels stronger after a dose.
Gabapentin has a more established role in treating certain forms of neuropathic pain, particularly painful diabetic neuropathy and pain following shingles. Cannabis-based medicines may help some patients, but average benefits are generally modest and important uncertainties remain. Neither treatment has been shown to reliably repair damaged nerves, and strong clinical evidence does not establish marijuana as superior to gabapentin.
First, Identify What Is Causing the Neuropathy
Neuropathy describes nerve damage or dysfunction, rather than one specific disease. Diabetes, vitamin deficiencies, chemotherapy, alcohol exposure and nerve compression can produce different patterns of symptoms. Neuropathic pain can also arise from damage within the brain or spinal cord. This distinction matters because evidence from one condition cannot automatically be applied to another. A treatment studied after spinal cord injury, for example, may not produce the same results in someone with diabetic nerve damage.
The National Institute of Neurological Disorders and Stroke emphasizes treating the underlying cause alongside symptoms. Correcting a deficiency or addressing nerve compression may be more consequential than changing pain medication. People with diabetes also need ongoing glucose management and foot care. Reduced pain does not necessarily mean that sensation, balance or protective awareness has returned. Someone whose feet feel more comfortable can still develop an unnoticed injury, so pain relief should complement disease management and daily foot checks.
How Well Does Gabapentin Work for Nerve Pain?
Gabapentin is an anticonvulsant also used for neuropathic pain. In the United States, its pain indication includes postherpetic neuralgia, the persistent nerve pain that can follow shingles; its use for painful diabetic neuropathy is off-label. A major review by Wiffen and colleagues in the Cochrane Database of Systematic Reviews in 2017 included 37 studies involving 5,914 participants. In painful diabetic neuropathy trials using at least 1,200 milligrams daily, 38% of participants receiving gabapentin achieved substantial benefit, compared with 23% receiving placebo. Substantial benefit meant at least 50% pain relief or reporting very much improved overall symptoms.
That difference supports gabapentin as a legitimate option while showing its limitations: many participants did not obtain substantial relief. Evidence was strongest for diabetic neuropathy and postherpetic neuralgia, with much less certainty for other conditions. These trial doses describe research, not a starting-dose recommendation. Clinicians individualize treatment and assess whether improved comfort translates into better sleep or activity. An unsuccessful trial is a reason to reconsider the plan, rather than assume that progressively higher doses will inevitably work.
What Does Cannabis Research Actually Show?
Cannabis research covers several distinct treatments, including THC-containing extracts, synthetic cannabinoids and CBD. Chou and colleagues’ updated review in Annals of Internal Medicine in 2026 analyzed 25 short-term randomized trials involving 2,303 participants, mostly with neuropathic pain. Certain oral THC products and balanced THC–CBD mouth sprays produced small average improvements. Differences from placebo were approximately 0.78 and 0.54 points, respectively, on a 10-point pain scale. Dizziness, sedation and nausea increased, and the findings did not establish comparable benefits for every product sold as medical marijuana.
The 2026 Cochrane review by Ateş and colleagues examined 21 studies involving 2,187 participants and reached cautious conclusions. Evidence remained uncertain for substantial pain relief with THC-dominant, balanced THC–CBD and CBD-dominant medicines. Balanced products may modestly increase the proportion achieving at least 30% relief, while also increasing treatment discontinuation because of adverse effects. These findings can coexist with small average improvements: reducing a group’s average pain score is different from demonstrating that many individuals achieve major relief. Most studies were brief, leaving long-term effectiveness less certain.
Is CBD an Effective Alternative Without the High?
CBD deserves separate discussion because it does not produce THC’s characteristic intoxication. However, being non-intoxicating does not establish effectiveness for neuropathy. Earlier evidence syntheses found limited or inconsistent benefits from CBD-dominant treatments. A newer trial by Robertson and colleagues, published in eClinicalMedicine in 2026, provides a promising but narrow finding. Researchers studied oral CBD at doses titrated up to 800 milligrams daily in people with neuropathic pain following spinal cord injury. Thirty-eight participants were included in the primary analysis of this randomized, placebo-controlled crossover trial.
During the six-week treatment periods, CBD reduced pain by approximately 0.54 points more than placebo on a 10-point scale. The improvement was statistically significant but modest, and adverse events were more common during CBD treatment, although nearly all were minor. This study supports further investigation; it does not establish CBD as equivalent to gabapentin or validate low-dose gummies and creams. The population, formulation and dose were specific, and the study did not answer whether CBD helps diabetic neuropathy or remains beneficial over years.
Have Cannabis and Gabapentin Been Compared Directly?
Direct comparisons are limited, but it would be inaccurate to say none exist. Bestard and Toth reported an open-label comparison of nabilone and gabapentin in Pain Practice in 2011. Patients with painful peripheral neuropathy received these medicines as standalone or additional treatment. Pain improved across treatment groups over six months, and the authors described apparently comparable benefits. However, treatment assignment was not randomized, and patients and investigators knew which medicines were being used. Those features make expectations, patient selection and other differences difficult to separate from treatment effects.
Nabilone is also a synthetic cannabinoid medicine, rather than dispensary cannabis. Its findings cannot establish that a particular flower, oil or edible matches gabapentin. Similarly, comparing response percentages from unrelated placebo-controlled studies does not create a reliable ranking. Trials differ in diagnosis, previous treatment failures, dose, duration and the outcomes measured. The defensible conclusion is that gabapentin has a stronger established evidence base for certain neuropathies, while high-quality direct evidence remains insufficient to declare cannabis a better replacement.
How Do Side Effects and Safety Compare?
Gabapentin commonly causes dizziness and sleepiness, and some patients experience swelling or difficulty walking. Kidney function matters because gabapentin is eliminated through the kidneys, requiring dose adjustment when clearance is reduced. The FDA’s 2019 safety communication also warned about serious breathing problems in susceptible patients, particularly those taking opioids or other central nervous system depressants, people with respiratory disease and older adults. A medication review is especially important when neuropathy already affects balance or when several sedating medicines are prescribed together.
THC can impair attention, memory, coordination and driving, and may trigger anxiety or paranoia. Frequent use can lead to cannabis use disorder, while smoking adds respiratory exposure. These concerns are distinct from whether a product reduces pain. CBD generally avoids intoxication but can still cause adverse effects and interact with medications. Neither “natural” nor “prescription” is a reliable shortcut for determining safety. The relevant question is how a particular treatment affects someone’s alertness, mobility, mental health and ability to manage ordinary responsibilities.
Does the Form of Cannabis Make a Difference?
The term cannabis can obscure major differences in exposure. Inhaled THC acts relatively quickly, whereas swallowed products have delayed and more variable effects that can last longer. Taking additional edible doses before the first has fully taken effect can cause unexpectedly intense impairment. A cream applied to the feet is another distinct intervention and should not be assumed to reproduce results from oral medicines or mouth sprays. Findings about one route or formulation need to stay attached to that product.
For comparison purposes, product consistency is crucial. Gabapentin is supplied in standardized pharmaceutical doses, while cannabis products vary in THC–CBD content and formulation. A familiar strain name does not establish a reproducible treatment or predict success for neuropathy. Anyone discussing cannabis with a clinician should identify the actual product, cannabinoid amounts, route and frequency. That information makes it possible to evaluate exposure and side effects; simply reporting “medical marijuana” leaves too much uncertainty for a useful comparison.
Can Cannabis and Gabapentin Be Used Together?
Combining them can increase the practical burden of dizziness, drowsiness and impaired coordination. This is especially concerning for someone who already has reduced foot sensation, an unsteady gait or other sedating prescriptions. Evidence does not establish that adding cannabis routinely improves neuropathic pain enough to offset those risks. A study by Atwal and colleagues in Neuropharmacology in 2019 investigated THC–gabapentin interactions in a mouse model of neuropathic pain. Such experimental findings can justify further research, but they cannot establish a safe or effective combination regimen for patients.
Adding cannabis or replacing gabapentin should therefore involve the prescriber rather than an unsupervised substitution. Gabapentin should not be stopped abruptly; its prescribing information calls for gradual reduction, with the schedule individualized by the clinician. Changing several treatments simultaneously also makes it harder to identify what helped or caused a problem. Patients should disclose alcohol, sleep medicines, opioids and cannabis use, avoid driving while impaired, and seek urgent help for severe sedation or breathing difficulty.
What If Gabapentin Does Not Help?
The choice is broader than gabapentin versus cannabis. Price and colleagues’ American Academy of Neurology guideline update, published in Neurology in 2022, recommends offering established medication classes for painful diabetic neuropathy, including gabapentinoids, serotonin–norepinephrine reuptake inhibitors, tricyclic antidepressants and sodium-channel blockers. When one class fails to provide meaningful improvement or causes significant adverse effects, trying a different effective class is reasonable. Mood and sleep also deserve assessment because they influence the overall burden of pain and the goals of treatment.
The underlying diagnosis can change that sequence. For established painful chemotherapy-induced peripheral neuropathy, the 2020 American Society of Clinical Oncology guideline by Loprinzi and colleagues identified duloxetine as the only medication with appropriate supporting evidence, while acknowledging limited benefit. This illustrates why a general “nerve pain” label is not enough to choose treatment. Rehabilitation, balance support and strategies for managing pain-related distress may also help address problems that a medicine alone cannot resolve. Treatment should respond to the person’s specific limitations and diagnosis.
Choosing a Treatment Based on Meaningful Improvement
A useful treatment trial starts with concrete goals: fewer pain-related awakenings, greater walking tolerance or the ability to complete daily tasks. Record baseline symptoms and reassess both benefit and adverse effects after an agreed period. Feeling sleepy or less concerned about pain can matter to a patient, but it should not automatically be counted as improved physical function. Continuing a treatment makes sense when its real-world benefits justify its burdens, rather than simply because it produces a noticeable sensation.
For painful diabetic neuropathy and postherpetic neuralgia, gabapentin remains a more established option than cannabis. Cannabis-based treatment may warrant an individualized discussion when conventional approaches provide insufficient relief or are poorly tolerated, but the evidence supports measured expectations. A successful plan combines an accurate diagnosis, attention to the cause, a manageable safety profile and regular reassessment. The best choice is the treatment that produces sustained, meaningful improvement for that patient without unacceptable impairment.
